Pharmacogenetics of methylphenidate response in attention deficit/hyperactivity disorder: association with the dopamine transporter gene (SLC6A3)

Am J Med Genet B Neuropsychiatr Genet. 2008 Dec 5;147B(8):1425-30. doi: 10.1002/ajmg.b.30809.

Abstract

Pharmacogenetic studies investigating the 40-bp VNTR polymorphism at SLC6A3 and methylphenidate response have shown conflicting results and large differences in study design and efficacy endpoints. Our objective was to investigate the relation between the 3'-VNTR at SLC6A3 and variability in methylphenidate response in a sample of 141 ADHD children and adolescents, assessed before and after methylphenidate treatment with both clinical and neuropsychological outcome measures. 10-R homozygotes were significantly overrepresented in the low response group, but no genotype effect was shown in cognitive variables improvement. A meta-analysis of pharmacogenetic studies with comparable data (responders vs. non-responders) on a total of 475 subjects showed a significant association between the 10-10 genotype and low rates of methylphenidate response (mean Odds Ratio = 0.46; 95% CI [0.28-0.76]). Heterogeneity between these studies did not reach a significant level but, as publications with different endpoints were excluded from this meta-analysis, our results do not rule out a possible influence of study design.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Attention Deficit Disorder with Hyperactivity / diagnosis
  • Attention Deficit Disorder with Hyperactivity / drug therapy*
  • Attention Deficit Disorder with Hyperactivity / genetics
  • Central Nervous System Stimulants / therapeutic use*
  • Chi-Square Distribution
  • Child
  • DNA / genetics
  • DNA / isolation & purification
  • Dopamine Plasma Membrane Transport Proteins / genetics*
  • Genotype
  • Homozygote
  • Humans
  • Meta-Analysis as Topic
  • Methylphenidate / therapeutic use*
  • Microsatellite Repeats
  • Odds Ratio
  • Pharmacogenetics / methods*
  • Polymorphism, Genetic
  • Probability
  • Treatment Outcome

Substances

  • Central Nervous System Stimulants
  • Dopamine Plasma Membrane Transport Proteins
  • SLC6A3 protein, human
  • Methylphenidate
  • DNA